|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-2-16
|
|
pubmed:abstractText |
PRO95780 is a fully human IgG1 monoclonal antibody that triggers the extrinsic apoptosis pathway through death receptor 5. This first-in-human study assessed the safety, tolerability, pharmacokinetics, and any early evidence of efficacy of PRO95780 in patients with advanced malignancies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AshkenaziAviA,
pubmed-author:BrayGordonG,
pubmed-author:CamidgeD RossDR,
pubmed-author:DurbinBlytheB,
pubmed-author:EckhardtS GailSG,
pubmed-author:GordonMichael SMS,
pubmed-author:HerbstRoy SRS,
pubmed-author:IngJosephineJ,
pubmed-author:KurzrockRazelleR,
pubmed-author:MendelsonDavidD,
pubmed-author:SagerJasonJ,
pubmed-author:TohnyaTanyifor MTM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1256-63
|
|
pubmed:dateRevised |
2011-8-2
|
|
pubmed:meshHeading |
pubmed-meshheading:20145186-Aged,
pubmed-meshheading:20145186-Aged, 80 and over,
pubmed-meshheading:20145186-Antibodies, Monoclonal,
pubmed-meshheading:20145186-Antineoplastic Agents,
pubmed-meshheading:20145186-Female,
pubmed-meshheading:20145186-Humans,
pubmed-meshheading:20145186-Male,
pubmed-meshheading:20145186-Maximum Tolerated Dose,
pubmed-meshheading:20145186-Middle Aged,
pubmed-meshheading:20145186-Neoplasms,
pubmed-meshheading:20145186-Receptors, TNF-Related Apoptosis-Inducing Ligand
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
|
|
pubmed:affiliation |
Department of Medical Oncology, University of Colorado, Denver, Colorado, USA. ross.camidge@uchsc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
